UNSPSC 51294803: Gepirone hydrochloride

This classification denotes a serotonin agonist and anxiolytic with the molecular formula C19H29N5O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80C9L8EP6V, chemically known as 3,3-dimethyl-1-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)glutarimide monohydrochloride but more generally known as gepirone hydrochloride, which bears US NIH Compound Identifier 55190. Most nations, for tariff and trade purposes, schedule gepirone hydrochloride under HS 29335995 and SITC 51576.

As of Q4 2014, GEPIRONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Gepirone hydrochloride bears US NLM identifiers UMLS ID C2348751 and NCI Concept Code C72795. SMILES: CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3NCCCN3)C.CL.

UNSPSC 51294803 Gepirone hydrochloride is a Commodity code that nominally names a specific pharmaceutical active pharmaceutical ingredient, but recent state and local procurement activity under this code shows little alignment with the code's literal scope. The three recent opportunities posted under this classification involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs and pharmacy benefit management (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products distributed through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations explicitly reference gepirone hydrochloride or target this ingredient as a line item. The issuing bodies span county health departments, state HHS agencies, and multistate cooperative purchasing vehicles, but the code does not surface genuine demand for the specific pharmaceutical named in the taxonomy.

Geographic activity appears concentrated in Florida, Texas, and Minnesota based on the three most recent postings, with Minnesota's MMCAP vehicle extending reach to participating states including Oregon. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) seeks 1,900 units of naloxone and 800 drug deactivation systems annually through competitive bidding with quarterly deliveries. Texas HHS issued an RFI (HHS0017013, due April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription initiative outside traditional pharmacy benefit manager arrangements. Minnesota's MMCAP RFP (S1070000015802, due March 26, 2026) establishes multi-award contracts for generic pharmaceuticals and OTC products across participating state and local facilities, with awarded vendors effective July 1, 2026, and requiring compliance with cGMP, the Drug Supply Chain Security Act, and specific wholesaler relationships. The code does not show active state and local demand specifically for gepirone hydrochloride; vendors pursuing pharmaceutical opportunities at the state and local level should verify actual product requirements in notice details before relying on this code classification.